Efficacy of Lorlatinib in Treatment-Naïve Patients With ALK-Positive Advanced NSCLC Based on EML4-ALK Variant Type and TP53 Mutational Status
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced non-small cell lung cancer in relation to EML4::ALK variant type and ALK with or without TP53 mutations
J Thorac Oncol 2023 Aug 02;[EPub Ahead of Print], A Bearz, JF Martini, J Jassem, SW Kim, GC Chang, AT Shaw, DA Shepard, E Dall'O', A Polli, H Thurm, G Zalcman, MR Garcia Campelo, K Penkov, H Hayashi, B SolomonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.